Eosinophilia secondary to lenalidomide therapy

J Clin Pharm Ther. 2018 Apr;43(2):273-275. doi: 10.1111/jcpt.12611. Epub 2017 Aug 17.

Abstract

What is known and objective: Limited data are available on eosinophilia as a drug adverse event. We describe a case of eosinophilia from lenalidomide therapy.

Case description: A 50-year-old woman received lenalidomide, dexamethasone and cyclophosphamide as POEMS syndrome treatment. Eosinophil count rose during lenalidomide treatment and decreased in the periods off treatment. Naranjo nomogram suggested a probable association between the use of lenalidomide and eosinophilia.

What is new and conclusion: Eosinophilia has rarely been described with lenalidomide. This case shows a clear temporal relationship between lenalidomide and eosinophilia.

Keywords: adverse event; eosinophilia; lenalidomide.

Publication types

  • Case Reports

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use
  • Antineoplastic Agents, Hormonal / therapeutic use
  • Cyclophosphamide / therapeutic use
  • Dexamethasone / therapeutic use
  • Eosinophilia / chemically induced*
  • Female
  • Humans
  • Lenalidomide
  • Middle Aged
  • POEMS Syndrome / drug therapy
  • Thalidomide / adverse effects
  • Thalidomide / analogs & derivatives*
  • Thalidomide / therapeutic use

Substances

  • Angiogenesis Inhibitors
  • Antineoplastic Agents, Hormonal
  • Thalidomide
  • Dexamethasone
  • Cyclophosphamide
  • Lenalidomide